2,2,2-三氟-N-(9-氧代芴-2-基)乙酰胺 | 318-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 2,2,2-三氟-N-(9-氧代芴-2-基)乙酰胺
• 英文名称: 2-Trifluoroacetylaminofluoren-9-one
• 英文别名: 2,2,2-trifluoro-N-(9-oxofluoren-2-yl)acetamide
• CAS: 318-22-9
• 化学式: C₁₅H₈F₃NO₂
• 分子量: 291.22
• InChiKey: JBUUOKOKZCHZNB-UHFFFAOYSA-N

物化性质

• 熔点：
  245.5-246 °C
• 沸点：
  450.1±45.0 °C(Predicted)
• 密度：
  1.3963 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090

文献信息

• METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS
  申请人：Transfusion Health, LLC

  公开号：US20220315895A1

  公开（公告）日：2022-10-06

  This disclosure is directed to, inter alia, methods and systems for preparing oligopotent and unipotent progenitor cells of defined lineages in culture from an expanded source of CD34+ cells, media for making the same, and therapeutic compounds and compositions comprising the same for treatment a variety of diseases included, but not limited to, hematologic disorders, immune diseases, cancers, and infectious diseases.

  本公开涉及的是从扩增的CD34+细胞来源中在培养中准备定义谱系的寡能和单能祖细胞的方法和系统，用于制备相应的培养基，以及包含相应的治疗化合物和组合物，用于治疗各种疾病，包括但不限于血液学疾病、免疫性疾病、癌症和传染性疾病。
• COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE
  申请人：Transfusion Health, LLC

  公开号：US20200255371A1

  公开（公告）日：2020-08-13

  This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.
• [EN] METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS<br/>[FR] PROCÉDÉS DE FABRICATION DE PRÉCURSEURS OLIGOPOTENTS ET UNIPOTENTS
  申请人：TRANSFUSION HEALTH LLC

  公开号：WO2020223517A1

  公开（公告）日：2020-11-05

  This disclosure is directed to, inter alia, methods and systems for preparing oligopotent and unipotent progenitor cells of defined lineages in culture from an expanded source of CD34+ cells, media for making the same, and therapeutic compounds and compositions comprising the same for treatment a variety of diseases included, but not limited to, hematologic disorders, immune diseases, cancers, and infectious diseases.